Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsSTU:4DN +4.78%39 EV-to-EBITDA is -6.54 as of Aug. 20, 2026. GuruFocus rates STU:4DN with a GF Score™ of 39/100 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 402 Biotechnology companies, Denali Therapeutics ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Denali Therapeutics's enterprise value is €2,961.51 Mil.
Denali Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-452.86 Mil. Therefore, Denali Therapeutics's EV-to-EBITDA for today is -6.54.
The historical rank and industry rank for Denali Therapeutics's EV-to-EBITDA or its related term are showing as below:
STU:4DN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.2 Med: -8.17 Max: 168.03
Current: -6.51
During the past 11 years, the highest EV-to-EBITDA of Denali Therapeutics was 168.03. The lowest was -47.20. And the median was -8.17.
STU:4DN's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 14.41
vs STU:4DN: -6.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Denali Therapeutics's PE Ratio (TTM) for today is calculated as:
Denali Therapeutics's share price for today is €21.91.
Denali Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Denali Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4DN vs RCUS, ALMS, ELVN: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Denali Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's EV-to-EBITDA falls into.
Denali Therapeutics's current Enterprise Value is €2,961.51 Mil.
Denali Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-452.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (STU:4DN) has a EV-to-EBITDA of -6.54 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Denali Therapeutics. According to the industry distribution chart, Denali Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry.
Is Denali Therapeutics' EV-to-EBITDA too high?
Denali Therapeutics' current EV-to-EBITDA is -6.54. Based on the distribution chart, Denali Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Denali Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' EV-to-EBITDA compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #999999 out of 402 companies for EV-to-EBITDA. This places Denali Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 14.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.41, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Denali Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 14.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current EV-to-EBITDA is -6.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Denali Therapeutics (STU:4DN) is currently considered Significantly Overvalued. The current EV-to-EBITDA is -6.54. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current EV-to-EBITDA is -6.54 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score
Get the complete analysis for STU:4DN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4DN has been successfully added to your 
